2.1. Inclusion and exclusion criteria
This protocol is extracted from research article:
Electroacupuncture in treatment of Parkinson disease
Medicine (Baltimore), Jan 22, 2021; DOI: 10.1097/MD.0000000000023010

Clinical randomized controlled trials (RCTs) taking EA combined with L-dopa therapy for PD will be included.

Patients diagnosed of PD will participant without restrictions of age, gender, race, or duration of disease.

The intervention of the experiment group will be EA adjuvant with L-dopa, and of the control will be the L-dopa alone.

Assessment of effectiveness rate;

Overall symptom scores using The Unified Parkinson Disease Rating Scale (UPDRS) and Webster scale;

Motor symptom scores utilizing UPDRS III scale;

Dopamine(DA) content.

Nonmotor symptom scores employing UPDRS I scale;

Activities of daily living using UDPRS II;

Complications of treatment applying UPDRS IV;

Antioxidant ability: SOD activity and LPO content;

Content of inflammatory cytokines: tumor necrosis factor-α and interleukin-1β;

Adverse events.

Note: The content above has been extracted from a research article, so it may not display correctly.

Please log in to submit your questions online.
Your question will be posted on the Bio-101 website. We will send your questions to the authors of this protocol and Bio-protocol community members who are experienced with this method. you will be informed using the email address associated with your Bio-protocol account.

We use cookies on this site to enhance your user experience. By using our website, you are agreeing to allow the storage of cookies on your computer.